Ibio, Inc. (IBIO) — 10-Q Filings
All 10-Q filings from Ibio, Inc.. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (4)
-
iBio's R&D Surge Drives Wider Loss, Bolstered by $50M Capital Raise
— Nov 12, 2025 Risk: high
iBio, Inc. reported a net loss of $5.72 million for the three months ended September 30, 2025, an increase from a net loss of $3.99 million in the same period o -
iBio, Inc. Q3 2025: Revenue $0.22M, Net Loss $2.25M
— May 2, 2025 Risk: medium
iBio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $9.86 million and total liabilities of $3.71 million. For t -
iBio, Inc. Q2 2025: Assets $9.1M, Liabilities $1.9M
— Feb 10, 2025 Risk: medium
iBio, Inc. filed a 10-Q for the period ending December 31, 2024. The company reported total assets of $9.132 million and total liabilities of $1.856 million for -
iBio, Inc. Files 10-Q for Period Ending December 31, 2023
— Feb 9, 2024 Risk: medium
iBio, Inc. (IBIO) filed a Quarterly Report (10-Q) with the SEC on February 9, 2024. iBio, Inc. filed a 10-Q report for the period ending December 31, 2023. The
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX